Roth Capital Issues Negative Estimate for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Roth Capital lowered their Q2 2025 EPS estimates for shares of TriSalus Life Sciences in a note issued to investors on Wednesday, May 21st. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at ($0.29) EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the prior year, the company earned ($0.60) EPS.

Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Roth Mkm restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.93.

TriSalus Life Sciences Stock Performance

TLSI opened at $5.56 on Friday. The stock has a market capitalization of $179.43 million, a P/E ratio of -2.23 and a beta of 0.50. The company’s 50-day simple moving average is $5.42 and its two-hundred day simple moving average is $5.04. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $9.00.

Insider Transactions at TriSalus Life Sciences

In other news, insider Richard Marshak sold 6,597 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the transaction, the insider now owns 69,101 shares in the company, valued at $357,943.18. This represents a 8.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 16,125 shares of company stock worth $83,528 in the last quarter. Company insiders own 27.50% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently made changes to their positions in TLSI. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences during the 1st quarter worth approximately $187,000. Charles Schwab Investment Management Inc. bought a new stake in TriSalus Life Sciences during the 1st quarter worth approximately $55,000. Connective Capital Management LLC bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $140,000. Bridgeway Capital Management LLC raised its stake in TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock worth $326,000 after acquiring an additional 50,000 shares during the period. Finally, Bank of America Corp DE raised its stake in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after acquiring an additional 178,298 shares during the period. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.